4pa0

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 12: Line 12:
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/MYH7_HUMAN MYH7_HUMAN]] Muscle contraction.
[[http://www.uniprot.org/uniprot/MYH7_HUMAN MYH7_HUMAN]] Muscle contraction.
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Omecamtiv Mecarbil (OM) is a small molecule allosteric effector of cardiac myosin that is in clinical trials for treatment of systolic heart failure. A detailed kinetic analysis of cardiac myosin has shown that the drug accelerates phosphate release by shifting the equilibrium of the hydrolysis step towards products, leading to a faster transition from weak to strong actin-bound states. The structure of the human beta-cardiac motor domain (cMD) with OM bound reveals a single OM-binding site nestled in a narrow cleft separating two domains of the human cMD where it interacts with the key residues that couple lever arm movement to the nucleotide state. In addition, OM induces allosteric changes in three strands of the beta-sheet that provides the communication link between the actin-binding interface and the nucleotide pocket. The OM-binding interactions and allosteric changes form the structural basis for the kinetic and mechanical tuning of cardiac myosin.
 +
 +
Structural basis for drug-induced allosteric changes to human beta-cardiac myosin motor activity.,Winkelmann DA, Forgacs E, Miller MT, Stock AM Nat Commun. 2015 Aug 6;6:7974. doi: 10.1038/ncomms8974. PMID:26246073<ref>PMID:26246073</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
== References ==
== References ==
<references/>
<references/>

Revision as of 06:21, 20 August 2015

Omecamtiv Mercarbil binding site on the Human Beta-Cardiac Myosin Motor Domain

4pa0, resolution 2.25Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools